Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$498.5MCash on Hand
25.1mo Cash Runway
Follow MLTX by emailGet an email when MLTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MLTX, unsubscribe in one click. Privacy
📣 What MLTX Says Is Next
in November 2026 · “Palmoplantar pustulosis: The Company expects to commence enrollment in the Phase 3 NOVA trial as per plans in November 2026.”
Company press release, Nov 4, 2026 · SEC filing
early 2027 · “In addition, MoonLake expects results of the P-OLARIS trial to become available in early 2027.”
Company press release, Nov 4, 2026 · SEC filing
first quarter of 2027 · “The Company expects to announce initial topline results following a predefined unblinding protocol in the first quarter of 2027.”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 results: cash of $498.5 million, runway to mid-2028, and R&D expenses of $68.9 million, up from $50.2 million, mainly from accrued milestone license fees tied to expected BLA acceptance. BLA for sonelokimab in HS submitted to the FDA on September 30, 2026. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 30, 2026 ·
Regulatory MoonLake submitted a Biologics License Application to the FDA on September 30, 2026, seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 and older. The company expects FDA notice on acceptance within about 60 days and the review timeline within about 74 days. Form 8-K · SEC filing
Aug 10, 2026 ·
Clinical trial Positive topline Week 16 results from Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve psoriatic arthritis: ACR50 response of 42.1% with 60 mg induction, ACR20 66.5%, MDA 41.2%, PASI90 61%. Company also reported $537.0 million cash at June 30, 2026, runway to mid-2028. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Financing MoonLake filed a shelf registration for up to $300,000,000 of Class A ordinary shares under an existing Sales Agreement with Leerink Partners LLC, as amended on August 10, 2026. The base prospectus also covers preference shares, debt securities, warrants and units in amounts to be determined later. Form S-3ASR · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 3 · Active Trial · Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Registry primary completion date, not a results date
Feb 2028 · Phase 3 · Enrolling · A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis Registry primary completion date, not a results date
Jun 2028 · Phase 3 · Enrolling · A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa Registry primary completion date, not a results date
May 2026 · Phase 3 · Active Trial · Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not MLTX's own candidates): Risankizumab, Adalimumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MLTX holds $498.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $59.5M/quarter from operations,
an estimated runway of 25.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:20 · Moderate
Cash runway 25 months
ATM program on file since Aug 2026 +15
Shelf registration (S-3ASR, Aug 2026) +10
Company says cash lasts to mid-2028 -5Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures to mid-2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Aug 10, 2026 · Shelf registration with ATM program, up to $300M · S-3ASR
Share count 85,106,685 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MLTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MLTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.